Calcified Tissue International

, Volume 78, Issue 1, pp 35–44

The Receptor Activator of Nuclear Factor-κB Ligand Inhibitor Osteoprotegerin Is a Bone-Protective Agent in a Rat Model of Chronic Renal Insufficiency and Hyperparathyroidism

  • J. Padagas
  • M. Colloton
  • V. Shalhoub
  • P. Kostenuik
  • S. Morony
  • L. Munyakazi
  • M. Guo
  • D. Gianneschi
  • E. Shatzen
  • Z. Geng
  • H.-L. Tan
  • C. Dunstan
  • D. Lacey
  • D. Martin
Laboratory Investigations

Abstract

Osteoprotegerin (OPG) acts by neutralizing the receptor activator of nuclear factor-κB ligand (RANKL), the primary mediator of osteoclast differentiation, function, and survival. We examined whether OPG could affect the bone loss associated with chronic kidney disease (CKD) in a rodent model of CKD and secondary hyperparathyroidism (SHPT). SHPT was induced in rats by 5/6 nephrectomy (5/6 Nx) and a 1.2% P/0.6% Ca2+ diet. Starting 1 week after 5/6 Nx, rats were treated with vehicle (veh) or OPG-Fc (3 mg/kg, intravenously) every 2 weeks for 9 weeks. At baseline, 3, 6, and 9 weeks, blood was taken and bone mineral density (BMD) and bone mineral content (BMC) were assessed by dual-energy X-ray absorptiometry. Serum parathyroid hormone (sPTH) levels reached 912 pg/ml in 5/6 Nx rats vs. 97 pg/ml in shams at 9 weeks. OPG-Fc had no effect on sPTH or Ca2+ levels throughout the 9-week study, indicating that SHPT was a renal effect independent of bone changes. At 3 weeks, 5/6 Nx-veh rats had osteopenia compared with sham-veh rats and 5/6 Nx-OPG-Fc rats had significantly higher percent changes in whole-body BMC, leg BMD, and lumbar BMD versus 5/6 Nx-veh rats. By 6–9 weeks, elevated sPTH was associated with reversal of bone loss and osteitis fibrosa in the proximal tibial metaphysis. OPG-Fc decreased this sPTH-driven high bone turnover, resulting in augmented thickness of proximal tibial trabeculae in 5/6 Nx rats. Thus, RANKL inhibition with OPG-Fc can block the deleterious effects of continuously elevated sPTH on bone, suggesting that RANKL may be an important therapeutic target for protecting bone in patients with CKD and SHPT.

Keywords

Secondary hyperparathyroidism Chronic kidney disease Fibrous osteodystrophy Osteitis fibrosa 5/6 nephrectomy 

References

  1. 1.
    Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Boyle WJ (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309–319CrossRefPubMedGoogle Scholar
  2. 2.
    Lacey DL, Tan HL, Lu J, Kaufman S, Van G, Qiu W, Rattan A, Scully S, Fletcher F, Juan T, Kelley M, Burgess TL, Boyle WJ, Polverino AJ (2000) Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 157:435–448PubMedGoogle Scholar
  3. 3.
    Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337–342CrossRefPubMedGoogle Scholar
  4. 4.
    Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR (2001) The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 16:348–360PubMedCrossRefGoogle Scholar
  5. 5.
    Kostenuik PJ, Capparelli C, Morony S, Adamu S, Shimamoto G, Shen V, Lacey DL, Dunstan CR (2001) OPG and PTH-(1–34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. Endocrinology 142:4295–4304CrossRefPubMedGoogle Scholar
  6. 6.
    Capparelli C, Kostenuik PJ, Morony S, Starnes C, Weimann B, Van G, Scully S, Qi M, Lacey DL, Dunstan CR (2000) Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. Cancer Res 60:783–787PubMedGoogle Scholar
  7. 7.
    Akatsu T, Murakami T, Ono K, Nishikawa M, Tsuda E, Mochizuki SI, Fujise N, Higashio K, Motoyoshi K, Yamamoto M, Nagata N (1998) Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy. Bone 23:495–498CrossRefPubMedGoogle Scholar
  8. 8.
    Doran PM, Turner RT, Chen D, Facteau SM, Ludvigson JM, Khosla S, Riggs BL, Russell SJ (2004) Native osteoprotegerin gene transfer inhibits the development of murine osteolytic bone disease induced by tumor xenografts. Exp Hematol 32:351–359CrossRefPubMedGoogle Scholar
  9. 9.
    Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S (2001) Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 98:3527–3533CrossRefPubMedGoogle Scholar
  10. 10.
    Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand JP, Harousseau JL, Lipton A, Mariette X, Williams CD, Nakanishi A, Holloway D, Martin SW, Dunstan CR, Bekker PJ (2003) A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97(suppl 3):887–892PubMedCrossRefGoogle Scholar
  11. 11.
    Cheng X, Kinosaki M, Murali R, Greene MI (2003) The TNF receptor superfamily: role in immune inflammation and bone formation. Immunol Res 27:287–294PubMedCrossRefGoogle Scholar
  12. 12.
    Vanderkerken K, Asosingh K, Croucher P, Van Camp B (2003) Multiple myeloma biology: lessons from the 5TMM models. Immunol Rev 194:196–206CrossRefPubMedGoogle Scholar
  13. 13.
    Wittrant Y, Theoleyre S, Chipoy C, Padrines M, Blanchard F, Heymann D, Redini F (2004) RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta 1704:49–57PubMedGoogle Scholar
  14. 14.
    Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ (2001) Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 61:4432–4436PubMedGoogle Scholar
  15. 15.
    Bolon B, Shalhoub V, Kostenuik PJ, Campagnuolo G, Morony S, Boyle WJ, Zack D, Feige U (2002) Osteoprotegerin, an endogenous antiosteoclast factor for protecting bone in rheumatoid arthritis. Arthritis Rheum 46:3121–3135CrossRefPubMedGoogle Scholar
  16. 16.
    Goodman WG, Coburn JW, Slatopolsky E, Salusky IB, Quarles LD (2003) Renal osteodystrophy in adults and children. In: Favus MJ (ed), Primer on the metabolic bone diseases and disorders of mineral metabolism. American Society for Bone and Mineral Research, Washington DC, pp 430–447Google Scholar
  17. 17.
    Parfitt AM (1998) A structural approach to renal bone disease. J Bone Miner Res 13:1213–1220PubMedCrossRefGoogle Scholar
  18. 18.
    Jablonski G, Klem KH, Attramadal A, Dahl E, Ronningen H, Gautvik KM, Haug E, Gordeladze JO (1993) Surgically induced uremia in rats. I: Effect on bone strength and metabolism. Biosci Rep 13:275–287CrossRefPubMedGoogle Scholar
  19. 19.
    Jablonski G, Danielsen CC, Mosekilde L, Gordeladze JO (1994) Surgically induced uremia in rats. II: Osseous PTH-susceptible signaling systems as predictors of bone resorption. Calcif Tissue Int 55:281–287CrossRefPubMedGoogle Scholar
  20. 20.
    Miller MA, Chin J, Miller SC, Fox J (1998) Disparate effects of mild, moderate, and severe secondary hyperparathyroidism on cancellous and cortical bone in rats with chronic renal insufficiency. Bone 23:257–266CrossRefPubMedGoogle Scholar
  21. 21.
    Wada M, Ishii H, Furuya Y, Fox J, Nemeth EF, Nagano N (1998) NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int 53:448–453CrossRefPubMedGoogle Scholar
  22. 22.
    Jablonski G, Mortensen BM, Klem KH, Mosekilde L, Danielsen CC, Gordeladze JO (1995) Vitamin D3 analogs and salmon calcitonin partially reverse the development of renal osteodystrophy in rats. Calcif Tissue Int 57:385–391CrossRefPubMedGoogle Scholar
  23. 23.
    Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, LoRusso P, Ma P, Ravera C, Deckert F, Schran H, Seaman J, Skerjanec A (2002) Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 42:1228–1236PubMedCrossRefGoogle Scholar
  24. 24.
    Avbersek-Luznik I, Balon BP, Rus I, Marc J (2005) Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis? Nephrol Dial Transplant 20:566–570PubMedCrossRefGoogle Scholar
  25. 25.
    Huang JC, Sakata T, Pfleger LL, Bencsik M, Halloran BP, Bikle DD, Nissenson RA (2004) PTH differentially regulates expression of RANKL and OPG. J Bone Miner Res 19:235–244PubMedCrossRefGoogle Scholar
  26. 26.
    Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597–3602CrossRefPubMedGoogle Scholar
  27. 27.
    Chang JT, Green L, Beitz J (2003) Renal failure with the use of zoledronic acid. N Engl J Med 349:1676–1678PubMedCrossRefGoogle Scholar
  28. 28.
    Ammann P, Rizzoli R, Slosman D, Bonjour J-P (1992) Sequential and precise in vivo measurement of bone mineral density in rats using dual-energy X-ray absorptiometry. J Bone Miner Res 7:311–316PubMedCrossRefGoogle Scholar
  29. 29.
    Makan S, Bayley HS, Webber CE (1997) Precision and accuracy of total body bone mass and body composition measurements in the rat using X-ray-based dual photon absorptiometry. Can J Physiol Pharmacol 75:1257–1261CrossRefPubMedGoogle Scholar
  30. 30.
    Colloton M, Shatzen E, Miller G, Stehman-Ereen C, Wada M, Lacey DL, Martin D (2005) Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int 67:467–476CrossRefPubMedGoogle Scholar
  31. 31.
    Lee SK, Lorenzo JA (2002) Regulation of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin mRNA expression by parathyroid hormone is predominantly mediated by the protein kinase A pathway in murine bone marrow cultures. Bone 31:252–259PubMedCrossRefGoogle Scholar
  32. 32.
    Ma YL, Cain RL, Halladay DL, Yang X, Zeng Q, Miles RR, Chandrasekhar S, Martin TJ, Onyia JE (2001) Catabolic effects of continuous human PTH (1–38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinol 142:4047–4054CrossRefGoogle Scholar
  33. 33.
    Geng Z, Monier-Faugere MC, Bauss F, Malluche HH (2000) Short-term administration of the bisphosphonate ibandronate increases bone volume and prevents hyperparathyroid bone changes in mild experimental renal failure. Clin Nephrol 54:45–53PubMedGoogle Scholar
  34. 34.
    Moscovici A, Bernheim J, Popovtzer MM, Rubinger D (1996) Renal osteodystrophy in rats with reduced renal mass. Nephrol Dial Transplant 11(suppl 3):146–152PubMedGoogle Scholar
  35. 35.
    Kazama JJ, Iwasaki Y, Yamato H, Murayama H, Sato M, Gejyo F, Kurokawa M, Fukagawa K (2003) Microfocus computed tomography analysis of early changes in bone microstructure in rats with chronic renal failure. Nephron Exp Nephrol 95:e152–e157CrossRefPubMedGoogle Scholar
  36. 36.
    Capparelli C, Morony S, Warmington K, Adamu S, Lacey D, Dunstan CR, Stouch B, Martin S, Kostenuik PJ (2003) Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. J Bone Miner Res 18:852–858PubMedCrossRefGoogle Scholar
  37. 37.
    Markowitz GS, Fine PL, Stack JI, Kunis CL, Radhakrishnan J, Palecki W, Park J, Nasr SH, Hoh S, Siegel DS, D’Agati VD (2003) Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 64:281–289PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2005

Authors and Affiliations

  • J. Padagas
    • 1
  • M. Colloton
    • 1
  • V. Shalhoub
    • 1
  • P. Kostenuik
    • 1
  • S. Morony
    • 1
  • L. Munyakazi
    • 1
  • M. Guo
    • 1
  • D. Gianneschi
    • 1
  • E. Shatzen
    • 1
  • Z. Geng
    • 1
  • H.-L. Tan
    • 1
  • C. Dunstan
    • 2
  • D. Lacey
    • 1
  • D. Martin
    • 1
  1. 1.Department of Metabolic DisordersAmgen Inc, One Amgen Center DriveThousand Oaks
  2. 2.Anzac Research InstituteConcord HospitalConcordAustralia

Personalised recommendations